Existing and soon to be launched novel, high-priced, disease-modifying cystic fibrosis transmembrane conductance regulator (CFTR) modulators are anticipated to drive the cystic fibrosis market to $7.6bn by 2025, compared to $2.1bn in 2015, according to a report by GlobalData.
Titled ‘OpportunityAnalyzer: Cystic Fibrosis – Opportunity Analysis and Forecasts to 2025’, the report forecasts the cystic fibrosis market across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Canada to witness double-digit compound annual growth rate of 13.6% over the forecast period.
Therapies developed over the last decade enhance CFTR function, therefore targeting the underlying cause of cystic fibrosis and indicating a shift from previous research and development (R&D) efforts that targeted organ-specific sequelae.
Kalydeco (ivacaftor) and Orkambi by Vertex command the CFTR modulator market, says Pavan Kottamasu, MSc, Healthcare Analyst for GlobalData.
The majority of the companies developing novel therapeutic agents for the disease are small companies, resulting in a trend towards licensing of products by pharmaceutical and biotechnology companies by forming alliances, says Pavan Kottamasu.
Unmet needs in the space will still be significant due to the lack of curative therapies and limited availability of mucolytic therapies, adds the report.